Please login to the form below

Not currently logged in
Email:
Password:

Chiltern hires Roche’s Andrew Monaghan to head pharmacovigilance

He was global head of safety operations at pharma company

Roche's Andrew Monaghan has swapped pharma for clinical research by moving to Chiltern.

Monaghan, who was global head of safety operations at Roche, take on the role of director of global pharmacovigilance at the clinical research organisation Chiltern.

In this new role, he will lead Chiltern's pharmacovigilance team and expand the organisation's global pharmacovigilance offering.

“His strong leadership skills and extensive clinical experience will ensure our clients continue to receive customized and efficient safety solutions to meet their specific product and regulatory requirements, whether with investigational or postmarketed products,” said Dr Sharon Moore, executive VP, global medical and regulatory affairs.

Monaghan has served at Roche since 1997, when he joined as global head of PDO clinical management group.

Prior to this role he was director of regulatory affairs at Pfizer Global Research & Development.

25th July 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....